Ask what Korea is talking about.

Celltrion has unveiled the world's first quadruple-action obesity drug candidate, CT-G32/SCO-940, which targets four hormone pathways simultaneously. In animal studies, it showed greater weight loss and better preservation of lean mass compared to existing triple-action treatments, according to Business Korea and Chosun Ilbo. The preclinical results were presented at the TIDES conference in Amsterdam from Nov. 3-5, and the company plans to begin human clinical trials next year. Korean media, including Dong-A Ilbo and Chosun Ilbo, report the findings positively, highlighting the potential to reduce muscle loss while enhancing weight loss effects.